+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
KOPRAN

KOPRAN Share Price

 

 

Kopran live price: ₹182.4. It opened at ₹189 vs previous close ₹189; intraday high/low: ₹195/₹180. The 50 & 200 DMA stand at ₹178.03/₹163.13.

Kopran Performance

  • Today's Low
  • ₹180
  • Today's High
  • ₹195
  • 52 Week Low
  • ₹107
  • 52 Week High
  • ₹219
  • Open Price₹189
  • Previous Close₹189
  • Volume105,230
  • 50 DMA₹178.03
  • 100 DMA₹166.38
  • 200 DMA₹163.13

Kopran Chart

Investment Returns

  • Over 1 Month -3.53%
  • Over 3 Month + 35.8%
  • Over 6 Month + 17.87%
  • Over 1 Year + 0.86%

Smart Investing Starts Here Start SIP with Kopran for Steady Growth!

Invest Now

Kopran Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.2
  • PEG Ratio
  • -1
  • Market Cap Cr
  • 881
  • P/B Ratio
  • 1.7
  • Average True Range
  • 9.44
  • EPS
  • 5.33
  • Dividend Yield
  • 1.6
  • MACD Signal
  • 4.23
  • RSI
  • 46.69
  • MFI
  • 54.98

Latest Stock News Updates

Kopran Consolidated December 2023 Net Sales at Rs 158.92 crore, up 0.58% Y-o-Y

Kopran Standalone September 2023 Net Sales at Rs 98.64 crore, up 83.95% Y-o-Y

Kopran Consolidated March 2023 Net Sales at Rs 148.88 crore, up 4.95% Y-o-Y

Kopran Financials

Kopran Technicals

EMA & SMA

Current Price
₹182.40
-6.99 (-3.69%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹188.00
  • 50 Day
  • ₹178.00
  • 100 Day
  • ₹166.40
  • 200 Day
  • ₹163.10

Resistance and Support

185.71 Pivot Speed
  • R3 206.36
  • R2 200.58
  • R1 191.49
  • S1 176.62
  • S2 170.84
  • S3 161.75

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kopran Ltd. is a fully integrated pharmaceutical company, engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves global markets with a focus on innovation, quality, and regulatory compliance.

Kopran has an operating revenue of Rs. 683.82 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 5% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 27% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kopran Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-19 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-12 Quarterly Results
2025-07-29 Quarterly Results
2025-05-15 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-04 FINAL Rs.3.00 per share(30%)Final Dividend
View Kopran Dividend History Arrow

Kopran Shareholding Pattern

44.42%
0%
0.57%
0%
44.08%
10.93%

Kopran FAQs

Kopran share price is ₹182 As on 08 July, 2026 | 18:31

The Market Cap of Kopran is ₹880.7 Cr As on 08 July, 2026 | 18:31

The P/E ratio of Kopran is 34.2 As on 08 July, 2026 | 18:31

The PB ratio of Kopran is 1.7 As on 08 July, 2026 | 18:31

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23